|
Huge Alert On: (OTCBB:ESPH) - (OTCBB:ETCC) - (OTCBB:IMUC)
(M2 PressWIRE Via Acquire Media NewsEdge) Rochester NY -- www.otc-advisors.com names (OTCBB:ESPH)Ecosphere Technologies, Inc. , (OTCBB:ETCC) Environmental Tectonics Corp. , and (OTCBB:IMUC) ImmunoCellular Therapeutics, Ltd. its "Bulls of the day"!
Visit: www.otc-advisors.com for current profiles.
To feature your publicly traded company in our alerts email us at info@otc-advisors.com.
To sign up for our free newsletter or to be added to our Quarterly Investment Magazine visit http://www.otc-advisors.com/contact.htm
Also, you can receive up to the minute stock alerts via our Twitter/Facbook page. www.twitter.com/otcadvisors or www.facebook.com/pages/OTC-ADVISORS-LLC/259891872296
---------------------------
Visit: www.otc-advisors.com
About Ecosphere Technologies:
Ecosphere Technologies, Inc. (OTCBB:ESPH) is a diversified water engineering and environmental services company. The Company provides environmental services and technologies for use in large-scale and sustainable applications across industries, nations and ecosystems. For more information, please visit: www.ecospheretech.com.
News Today:
STUART, Fla., May 26, 2010 -- Ecosphere Technologies, Inc. (OTCBB:ESPH), a diversified water engineering and environmental services company, announces today that it was featured on ABC affiliate Channel 25 WPBF News last night at 4:00, 5:00, 6:00 and 11:00. Click the following link to watch the news clip:
http://www.wpbf.com/video/23674184/index.html
Dennis McGuire, CEO and CTO of Ecosphere Technologies, said, "We are experts in treating a wide variety of flowback and produced waters for major energy producers. What makes our patented Ecosphere Ozonix technology unique over all other methods that treat produced waters is that we do not use any liquid chemicals in our process. The equipment we will be deploying to the Gulf has just been completed and is our newest offshore technology specifically built for removing oil and chemicals from sea water. The current crisis in the Gulf demands our immediate attention and we expect to move our equipment to Louisiana over the next few days."
Make sure you are first to receive timely information on Ecosphere Technologies when it hits the newswire. Sign up for Ecosphere's email news alert system today at: http://www.ESPH-IR.com.
-------------------------------------
Visit: www.otc-advisors.com
About ETC
ETC was incorporated in 1969 in Pennsylvania. For over forty years, we have provided our customers with products, service and support. Innovation, continuous technological improvement and enhancement, and product quality are core values and critical to our success. We are a significant supplier and innovator in the following product areas: (1) software driven products and services used to create and monitor the physiological effects of flight; (2) high performance jet tactical flight simulation; (3) steam and gas sterilization; (4) testing and simulation devices for the automotive industry; (5) hyperbaric and hypobaric chambers; and (6) driving and disaster simulation systems.
We operate in two business segments - Training Services Group ("TSG") and Control Systems Group ("CSG"). Our core technologies in TSG include the design, manufacture and sale of training services which includes (1) software driven products and services used to create and monitor the physiological effects of flight; (2) high performance jet tactical flight simulation, and; (3) driving and disaster simulation systems, and in CSG include: (1) steam and gas sterilization; (2) testing and simulation devices for the automotive industry, and; (3) hyperbaric and hypobaric chambers. Product categories included in TSG are Aircrew Training Systems (ATS) and flight simulators, disaster management systems and entertainment applications. CSG includes sterilizers, environmental control devices and hyperbaric chambers along with parts and service support.
News Today:
SOUTHAMPTON, Pa., May 26, 2010 -- Environmental Tectonics Corporation's (OTC Bulletin Board: ETCC) ("ETC" or the "Company") NASTAR(R) Center will host this year's "Embassy Day", an exclusive educational training technology forum for military and technology attaches. Three ETC business units will showcase the latest in aerospace training technology and training programs for military, space, and first responder applications. Embassy Day is June 2nd and 3rd, 2010 at The Fairfax Hotel on Massachusetts Avenue in Washington, DC.
Showcased technologies include:
Aircrew Training Systems - military and civil flight training equipment and operational support services
NASTAR Center - aerospace training, research, and education programs and services
ADMS - first responder emergency management training solutions
Government organizations can benefit from proper training of their airmen, astronauts, and first responders. In most cases, complex systems are being operated by the individual, and often, within stressful environments. Having the right tools and training can be vital to the health and safety of the individual, and to mission success.
For countries with established training centers, ETC offers Aircrew Training Systems training equipment for purchase. For countries without their own training centers, ETC offers the use of its full-service NASTAR Center in Philadelphia, PA, featuring high-fidelity equipment and associated training curricula. For government agencies with emergency management offices, ETC provides the Advanced Disaster Management System (ADMS) to better prepare first responders for emergency scenarios.
ETC training equipment, curriculum, and services are present in 87 countries including the United States where they are utilized by the United States Air Force (USAF) and United States Navy (USN).
--------------------------------------
Visit: www.otc-advisors.com
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd., a development stage company, focuses on developing and commercializing therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens; peptide based immunotherapies targeting cancer stem cells; and monoclonal antibodies to diagnose and treat various cancers. The company is developing dendritic cell based vaccine product candidate that has completed phase 1 of clinical trial to treat glioblastoma multiforme, a type of brain tumor. It is also developing peptide based off-the-shelf vaccine to target glioblastoma multiforme and multiple cancer indications; and various monoclonal antibody product candidates targeting small cell lung cancer, pancreatic cancer, multiple myeloma, and ovarian cancer. ImmunoCellular Therapeutics, Ltd. has an option license agreement with Roche Group to acquire a license to develop and commercialize ICT-69, its monoclonal antibody product candidate targeting multiple myeloma and ovarian cancer. The company is based in Woodland Hills, California.
News Today:
LOS ANGELES, May 26, 2010 -- ImmunoCellular Therapeutics. Ltd. or "IMUC" (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, issued the following Letter to Shareholders today:
Dear Shareholder:
I wanted to update you on ImmunoCellular corporate and industry developments over the past six months, since my last letter to you. Today, your company is very different than it was in mid-November. We have announced promising clinical results for ICT-107, our dendritic cell-based cancer vaccine which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors, strengthened our balance sheet to fund a planned Phase II clinical trial of ICT-107 and seen a validation of immunotherapy as a treatment modality through Dendreon's FDA clearance. These developments have positioned IMUC to create significant shareholder value in 2010 and beyond.
Some of the recent highlights include:
-- Strengthened balance sheet. In the last three months alone, the Company has raised approximately $8.5 million. We will continue to manage our cash conservatively, which historically has resulted in cash consumption of approximately $650,000 per quarter. Of course, our cash expenditures will increase as we accelerate our clinical and other research and development activities, but we should now have sufficient working capital to initiate and complete patient enrollment for our Phase II trial for ICT-107 and to pursue other clinical programs.
-- Reported impressive Phase I results for ICT-107 in a GBM trial. The Company recently announced top-line results, which demonstrated a median progression free survival for patients who received the vaccine of 17.7 months. We will be presenting new data on 18 and 24-month disease free survival and overall survival, as well as the full results of the trial at the 2010 American Society of Clinical Oncology Annual Meeting in Chicago on June 6th. While this trial involved a limited number of patients, we believe that this data represents the most impressive results reported to date from any trial for a GBM vaccine.
-- Sought Orphan Drug Status for ICT-107. The Company submitted an application for orphan drug status for ICT-107 in May and anticipates approval within the next 90 days.
The Company recently entered into a sponsored research agreement and an option agreement with The University of Pennsylvania ("UPenn") to support process development and manufacturing for the upcoming Phase II clinical trial of ICT-107. The UPenn agreement will include process optimization with the goal of increasing yields such that in a single manufacturing run enough doses could be produced for 2-3 years of each patient's vaccination and reduce the cost of manufacturing of each dose significantly. In addition, the optioned dendritic cell production technologies developed at UPenn could result in a higher potency as well as reduced time to manufacture these vaccines.
As part of our efforts to broaden the applications for our cancer vaccine technology platform, we have shown that our dendritic cell-based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in a preclinical animal model of GBM. The rats were either immunized with cancer stem cells (CSCs) from a brain cancer tumor or the daughter cells (the bulk of the tumor), and results showed that those immunized with the CSCs had a median survival of 50 days compared to 29 days for daughter cells. 30% of the animals vaccinated against cancer stem cells demonstrated long term survival as compared to animals vaccinated with the bulk of the tumor, all of which died.
We also continue to develop other cancer vaccine programs. We recently reported that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting. The parties have extended their research agreement to pursue additional studies to support an Investigational New Drug Application (IND) filing for ICT-121, our "off the shelf" cancer vaccine candidate for GBM, and other solid tumor cancers, as well as research on other cancer stem cell targets such as Numb and Notch proteins which are expressed on CSCs. Additional pre-clinical studies are underway to support the IND filing, which we hope to make in late 2010.
Our industry also made a significant achievement this year, in the announcement of the approval of Dendreon Corporation's prostate cancer vaccine by the FDA, which will result in the introduction of the first therapy utilizing the body's immune system to destroy tumors. The approval marks the first cancer immunotherapy product approved in the U.S., and we believe that it helps to validate immunotherapy treatments such as ours as a promising way to treat cancer. Our company is developing the next-generation of cancer vaccines by targeting multiple antigens and targeting cancer stem cells, widely held to be the root of most forms of cancer.
We are excited to present data at ASCO and to commence a Phase II trial in GBM this year to validate the promising results to date. We look forward to sharing these, and other corporate developments with our shareholders in the coming months.
Sincerely, Manish Singh, Ph.D. President and CEO
--------------------------------------
Visit: www.otc-advisors.com
About OTC-ADVISORS.COM
OTC-ADVISORS.COM is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTC-ADVISORS. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
For additional information: info@otc-advisors.com, www.otc-advisors.com, www.twitter.com/otcadvisors or www.facebook.com/pages/OTC-ADVISORS-LLC/259891872296
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]
|
